WASHINGTON (AP) Colon cancer. Uterine cancer. Pancreatic cancer.

Whatever the tumor, the more gene mutations lurking inside, the better chance your immune system has to fight back.

Thats the premise behind the recent approval of a landmark drug, the first cancer therapy ever cleared based on a tumors genetics instead of the body part it struck first.

Now thousands of patients with worsening cancer despite standard treatment can try this immunotherapy as long as genetic testing of the tumor shows theyre candidates.

Its like having a lottery ticket, said Johns Hopkins oncologist Dr. Dung Le, who helped prove the new use for the immunotherapy Keytruda. Weve got to figure out how to find these patients, because its such a great opportunity for them.

Today, doctors diagnose tumors by where they originate breast cancer in the breast, colon cancer in the colon and use therapies tested specifically for that organ.

In contrast, the Food and Drug Administration labeled Keytruda the first tissue-agnostic treatment, for adults and children.

Seemingly unrelated cancers occasionally carry a common genetic flaw called a mismatch repair defect. Despite small studies, the FDA found the evidence convincing that for a subset of patients, that flaw can make solid tumors susceptible to immunotherapy doctors otherwise wouldnt have tried.

We thought these would be the hardest tumors to treat, but its like an Achilles heel, said Hopkins cancer geneticist Bert Vogelstein.

Last month, FDA Commissioner Scott Gottlieb told a Senate subcommittee his agency will simplify drug development for diseases that all have a similar genetic fingerprint even if they have a slightly different clinical expression.

Its too early to know if whats being dubbed precision immunotherapy will have lasting benefits, but heres a look at the science.

WHOS A CANDIDATE?

Hopkins estimates about 4 percent of cancers are mismatch repair-deficient, potentially adding up to 60,000 patients a year.

Widely available tests that cost $300 to $600 can tell whos eligible.

The FDA said the flaw is more common in colon, endometrial and gastrointestinal cancers but occasionally occurs in a list of others.

Say, have I been tested for this? is Les advice for patients.

MUTATIONS AND MORE MUTATIONS

Most tumors bear 50 or so mutations in various genes, Vogelstein said. Melanomas and lung cancers, spurred by sunlight and tobacco smoke, may have twice as many. Tumors with a mismatch repair defect can harbor 1,500 mutations.

Why? When DNA copies itself, sometimes the strands pair up wrong to leave a typo a mismatch. Normally the body spell checks and repairs those typos.

Without that proofreading, mutations build up, not necessarily the kind that trigger cancer but bystanders in a growing tumor.

THE PLOT THICKENS

Your immune system could be a potent cancer fighter except that too often, tumors shield themselves.

Mercks Keytruda and other so-called checkpoint inhibitors can block one of those shields, allowing immune cells to recognize a tumor as a foreign invader and attack. Until now, those immunotherapies were approved only for a few select cancers Keytruda hit the market for melanoma in 2014 and they work incredibly well for some patients but fail in many others.

Learning whos a good candidate is critical for drugs that can cost $150,000 a year and sometimes cause serious side effects.

In 2012, Hopkins doctors testing various immunotherapies found the approach failed in all but one of 20 colon cancer patients. When perplexed oncologists told Vogelstein, a light bulb went off.

Sure enough, the one patient who fared well had a mismatch repair defect and a mind-boggling number of tumor mutations. The more mutations, the greater the chance that at least one produces a foreign-looking protein that is a beacon for immune cells, Vogelstein explained.

It was time to see if other kinds of cancer might respond, too.

WHATS THE DATA?

The strongest study, published in the journal Science, tested 86 such patients with 12 different cancers, including some who had entered hospice. Half had their tumors at least shrink significantly and 18 saw their cancer become undetectable.

Its not clear why the other half didnt respond. Researchers found a hint, in three patients, that new mutations might form that could resist treatment.

But after two years of Keytruda infusions, 11 of the complete responders have stopped the drug and remain cancer-free for a median of eight months and counting.

Catherine Katie Rosenbaum, 67, is one of those successes. The retired teacher had her uterus removed when endometrial cancer struck, but five years later tumors returned, scattered throughout her pelvis and colon.

She tried treatment after treatment until in 2014, her doctor urged the Hopkins study.

Rosenbaum took a train from Richmond, Virginia, to Baltimore for infusions every two weeks and then, after some fatigue and diarrhea side effects, once a month. Then the side effects eased and her tumors started disappearing.

A year into the study she was well enough to swim a mile for a Swim Across America cancer fundraiser.

Nothing else had worked, so I guess we could say it was a last hope, said Rosenbaum, who now wants other patients to know about the option.

Original post:
Immunotherapy drug targets tumor's genetics instead of body part - Monroe Evening News